Scientists say that a triple attack on bowel cancer can block drug resistance


A "third attack" using a combination of drugs could overcome the challenges of resistance to gut cancer, according to new research.

A multi-drug approach similar to that used to treat HIV and tuberculosis was successful in early experiments when cells stopped development in order to develop resistance.

This could help patients with colorectal cancer receive treatment for a longer period of time and prevent the tumor from starting to grow again, according to a study published in the Oncogene magazine.

Researchers at the London Institute of Cancer Research (ICR) said that this approach could prove to be effective in other types of cancer.

"Cancer patients initially often respond very well to modern target drugs, but there is always a concern that cancer will develop in order to resist treatment," said Professor Worker, co-author of the study and chief executive officer of the ICR.

"Our study analyzed the process by which cancer cells develop on the gut to become drug-resistant, and gained the knowledge gained in designing a new triple combination therapy."

The researchers examined 47 cell lines of colon cancer and initially found that cobimeticib and pictilisib contributed to the prevention of cancer growth.

After eight to ten weeks, the response cells developed resistance to the combination.

However, the exposure of cells to the third product, called navitoklax, for several weeks, prevented their resistance.

Professor Workman said: "Further research is needed, but we believe that this triple combination of target medicines has the potential to help patients respond to treatment much longer."

"Our study demonstrates the potential for using more targeted drugs together to overcome resistance to cancer drugs, just like in other diseases, such as HIV," said Dr. Paul Clarke, author of the study from the Institute of Cancer Research.

"We have shown that a three-fold attack can be effective against cancer cells in the gut by preventing their various pathways to get out of treatment.

"Research is still at a fairly early stage, but in principle combinations of target medicines could be similarly effective against many other types of cancer."


Source link